What is Bionyra Pharma?
Bionyra Pharma is a biotechnology company dedicated to pioneering natural-product-based therapeutics aimed at addressing pain and improving human health conditions. The company distinguishes itself by integrating advanced research methodologies, artificial intelligence, and sophisticated drug delivery systems to create a new generation of science-driven natural medicines. This approach underscores Bionyra Pharma's commitment to leveraging nature's potential through rigorous scientific validation.
How much funding has Bionyra Pharma raised?
Bionyra Pharma has raised a total of $165M across 1 funding round:
Series A
$165M
Series A (2026): $165M with participation from Sanofi Ventures, Sixty Degree Capital, Vives, Sofinnova Partners, Jeito, Arkin Holdings, and Apollo Health Ventures
Key Investors in Bionyra Pharma
Sanofi Ventures
Sanofi Ventures, the corporate venture capital arm of Sanofi, focuses on early-stage biotech and digital health companies with innovative technologies of strategic interest to Sanofi, particularly in oncology, immunology, rare diseases, and digital health.
Sixty Degree Capital
Sixty Degree Capital is a global investment firm specializing in healthcare and technology, partnering with founders to accelerate growth in areas like AI, drug development, and digital health from pre-seed to growth stages.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, actively building companies across the entire value chain from seed to later-stage, with a focus on healthcare and sustainability.
What's next for Bionyra Pharma?
The substantial enterprise-level funding, particularly the recent major strategic investment, signals Bionyra Pharma's transition into a scaling phase. This capital will likely be allocated towards accelerating clinical trials, expanding research and development capabilities, and potentially scaling manufacturing operations. The involvement of prominent life sciences investors suggests a strong validation of Bionyra's therapeutic approach and market potential, paving the way for future growth and market penetration in the competitive biotechnology landscape.
See full Bionyra Pharma company page
